Literature DB >> 21317834

Geographic atrophy in retinal angiomatous proliferation.

Vikki A McBain1, Reena Kumari, John Townend, Noemi Lois.   

Abstract

PURPOSE: To describe the occurrence of geographic atrophy in patients with retinal angiomatous proliferation (RAP).
METHODS: Demographics, visual acuity, color fundus photographs, fluorescein and indocyanine green angiograms, and fundus autofluorescence and near-infrared autofluorescence images were reviewed in 53 patients (66 eyes) with RAP.
RESULTS: Of 53 treatment-naive eyes, 19 (36%) had atrophy at baseline. Of 66 eyes, 57 (86%) developed de novo atrophy or enlargement of preexisting areas of atrophy during the follow-up (median, 17 months; range, 3-53 months) after treatment. Areas of atrophy were observed at the site of the RAP (58 of 66 eyes, 88%) of a previously existing pigment epithelial detachment (18 of 44 eyes; 41%) and elsewhere (43 of 66 eyes, 65%). At presentation, RAP was found to be frequently associated with increased autofluorescence at the fovea because of cystoid macular edema (36 of 53 eyes, 68%) and reduced autofluorescence because of hard exudation (38 of 53 eyes, 72%) and intraretinal hemorrhages (32 of 53 eyes, 60%). Background reticular (39%) and homogeneous (36%) autofluorescence were most commonly observed.
CONCLUSION: Geographic atrophy occurs frequently in patients with RAP after treatment. This information, if confirmed in other cohorts, would be valuable for the counseling of patients with this disease and for the understanding of the pathogenesis of this condition and its progression after treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21317834     DOI: 10.1097/IAE.0b013e3181fe54c7

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  20 in total

1.  Long-term visual outcome and prognostic factors of Intravitreal anti-vascular endothelial growth factor treatment for retinal angiomatous proliferation.

Authors:  Han Joo Cho; Tae Gon Lee; Sang Youn Han; Hyoung Seok Kim; Jae Hui Kim; Jung Il Han; Young Ju Lew; Jong Woo Kim
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-04-01       Impact factor: 3.117

2.  [Intravitreal ranibizumab for the treatment of retinal angiomatous proliferation].

Authors:  J Maaß; D Sandner; E Matthé
Journal:  Ophthalmologe       Date:  2017-06       Impact factor: 1.059

3.  Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients.

Authors:  Waheeda Rahman; Fred Kuanfu Chen; Jonathan Yeoh; Lyndon da Cruz
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-17       Impact factor: 3.117

4.  Analysis of short-term change in subfoveal choroidal thickness in eyes with age-related macular degeneration using optical coherence tomography.

Authors:  Jordana G Fein; Lauren A Branchini; Varsha Manjunath; Caio V Regatieri; James G Fujimoto; Jay S Duker
Journal:  Ophthalmic Surg Lasers Imaging Retina       Date:  2014 Jan-Feb       Impact factor: 1.300

Review 5.  Characterisation of macular neovascularisation subtypes in age-related macular degeneration to optimise treatment outcomes.

Authors:  Thibaud Mathis; Frank G Holz; Sobha Sivaprasad; Young Hee Yoon; Nicole Eter; Lee-Jen Chen; Adrian Koh; Eduardo Cunha de Souza; Giovanni Staurenghi
Journal:  Eye (Lond)       Date:  2022-09-14       Impact factor: 4.456

6.  Clinical features associated with the atrophy of fellow eyes in patients with unilateral type 3 macular neovascularization.

Authors:  Mihyun Choi; Eun Gyu Yoon; Ki Tae Nam; Cheolmin Yun
Journal:  Int Ophthalmol       Date:  2022-09-04       Impact factor: 2.029

7.  Chorioretinal thickness and retinal pigment epithelial degeneration of fellow eyes in patients with unilateral neovascular age-related macular degeneration with subretinal drusenoid deposits.

Authors:  Dongwan Kang; Eun Gyu Yoon; Ki Tae Nam; Cheolmin Yun
Journal:  BMC Ophthalmol       Date:  2022-07-14       Impact factor: 2.086

8.  Two-year results of combined intravitreal ranibizumab and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano; Kanako Itagaki
Journal:  Jpn J Ophthalmol       Date:  2016-01       Impact factor: 2.447

9.  Two-year results of combined intravitreal anti-VEGF agents and photodynamic therapy for retinal angiomatous proliferation.

Authors:  Masaaki Saito; Tomohiro Iida; Mariko Kano
Journal:  Jpn J Ophthalmol       Date:  2012-12-04       Impact factor: 2.447

10.  Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials.

Authors:  Juan E Grunwald; Ebenezer Daniel; Jiayan Huang; Gui-Shuang Ying; Maureen G Maguire; Cynthia A Toth; Glenn J Jaffe; Stuart L Fine; Barbara Blodi; Michael L Klein; Alison A Martin; Stephanie A Hagstrom; Daniel F Martin
Journal:  Ophthalmology       Date:  2013-09-29       Impact factor: 12.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.